Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Walid Shalata, Amjad Abu-Salman, Rachel Steckbeck, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5218-5218
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging
Sophie Mavrogeni, Alessia Pepe, Robin Nijveldt, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 9, pp. e308-e322
Open Access | Times Cited: 45
Immune Checkpoint Inhibitors—Associated Cardiotoxicity
Chenghui Li, Sajjad Bhatti, Jun Ying
Cancers (2022) Vol. 14, Iss. 5, pp. 1145-1145
Open Access | Times Cited: 39
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova La
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1243-1243
Open Access | Times Cited: 30
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
Ruichen Gao, Wenjun Liang, Jintao Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Laura I. Yousif, Elles M. Screever, Daniëlle Versluis, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 7, pp. 753-763
Open Access | Times Cited: 16
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Chiara Tommasi, Rita Balsano, Matilde Corianò, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 23, pp. 7239-7239
Open Access | Times Cited: 24
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
Walid Shalata, Sarah Weissmann, Sapir Itzhaki Gabay, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5451-5451
Open Access | Times Cited: 23
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
Walid Shalata, Jeremy Zolnoorian, Gabrielle Migliozzi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5938-5938
Open Access | Times Cited: 14
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
Vincenzo Quagliariello, Margherita Passariello, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential
Jan Jakub Lica, Bhaskar Pradhan, Kawthar Safi, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4280-4280
Open Access | Times Cited: 5
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Welche Immuntherapien sind heute schon Standard? Und mit welchen Nebenwirkungen muss man bei Immuntherapien rechnen?
Zhala Gasimova, Cyrus Khandanpour, Kim Luley, et al.
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie (2025) Vol. 150, Iss. 02, pp. 170-174
Closed Access
A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis
Shoichiro Saito, Shigeto Hontsu, J Hiraoka, et al.
Internal Medicine (2024)
Open Access | Times Cited: 4
Clinical Applications and Advancements of Positron Emission Tomography/Computed Tomography in Cardio-Oncology: A Comprehensive Literature Review and Emerging Perspectives
Ayman Battisha, Chitsimran Mann, Rutu Raval, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 11, pp. 1442-1451
Closed Access | Times Cited: 4
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Helena T. Wu, Van Doren Hsu, Shwe Win, et al.
Visualized Cancer Medicine (2025) Vol. 6, pp. 1-1
Open Access
SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights
Carl Simela, John M. Walker, Arjun K. Ghosh, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study
Fu-Xiao Li, Jiaxin Cai, Jibin Li, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
Song Huang, Yu Kang, Ting Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review
Haixia Yang, Menglu Sun, Xiaohong Zhou, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Role of Endomyocardial Biopsy in Diagnostics of Myocarditis
Līga Vīduša, Oskars Kalējs, Aija Maca-Kaleja, et al.
Diagnostics (2022) Vol. 12, Iss. 9, pp. 2104-2104
Open Access | Times Cited: 17
Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review
Lina Su, Chuan‐Fen Liu, Wenjie Wu, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 16
Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
Ioannis Trontzas, Ioannis Vathiotis, Konstantinos G. Kyriakoulis, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2637-2637
Open Access | Times Cited: 10
Unexpected Adverse Events of Immune Checkpoint Inhibitors
Walid Shalata, Alexander Yakobson, Aharon Y. Cohen, et al.
Life (2023) Vol. 13, Iss. 8, pp. 1657-1657
Open Access | Times Cited: 10
Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis
Fabrice Yves Ndjana Lessomo, Zhiquan Wang, Chishimba Mukuka
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top